Insulin-like growth factor-I and cancer mortality in older men

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 3, 2010, Pages 1054-1059

  Major, Jacqueline M ^a,b   Laughlin, Gail A ^a   Kritz Silverstein, Donna ^a   Wingard, Deborah L ^a   Barrett Connor, Elizabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ADULT; AGED; AGING; ARTICLE; CANCER MORTALITY; DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SERUM; STATISTICAL SIGNIFICANCE;

EID: 77749267659     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1378     Document Type: Article

References (32)

1. American Cancer Society 2007 Cancer Facts and Figures. Atlanta: American Cancer Society
2. Moschos SJ, Mantzoros CS 2002 The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63:317-332
3. Pollak M 2000 Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224-1228
4. Djavan B, Waldert M, Seitz C, Marberger M 2001 Insulin-like growth factors and prostate cancer. World J Urol 19:225-233
5. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC 1997 Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57:4667-4672
6. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, Le Roith D, Yakar S 2003 Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 63:4384-4388
7. Wu Y, Yakar S, Zhao L, Hennighausen L, Le Roith D 2002 Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62:1030-1035
8. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346-1353
9. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN,Hankinson SE 2006 Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13:583-592
10. Yu H, Jin F, Shu XO, Li BD, Dai Q, Cheng JR, Berkel HJ, Zheng W 2002 Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 11:705-712
11. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566
12. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGFbinding protein-3. J Natl Cancer Inst 91:620-625
13. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE 2000 A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9:345-349
14. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X 1999 Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-156
15. Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R 2002 Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 101:549-554
16. Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D 2004 Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomarkers Prev 13:438-444
17. Lönn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D 2007 Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiol Biomarkers Prev 16:844-846
18. Lin Y, Tamakoshi A, Kikuchi S, Yagyu K, Obata Y, Ishibashi T, Kawamura T, Inaba Y, Kurosawa M, Motohashi Y, Ohno Y 2004 Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer 110:584-588
19. Wakai K, Ito Y, Suzuki K, Tamakoshi A, Seki N, Ando M, Ozasa K, Watanabe Y, Kondo T, Nishino Y, Ohno Y, Group JS 2002 Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Jpn J Cancer Res 93:1279-1286
20. Saydah S, Graubard B, Ballard-Barbash R, Berrigan D 2007 Insulinlike growth factors and subsequent risk of mortality in the United States. Am J Epidemiol 166:518-526
21. Friedrich N, Haring R, Nauck M, Lüdemann J, Rosskopf D, Spilcke-Liss E, Felix SB, Dörr M, Brabant G, Völzke H, Wallaschofski H 2009 Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab 94: 1732-1739
22. Criqui MH, Barrett-Connor E, Austin M 1978 Differences between respondents and non-respondents in a population-based cardiovascular disease study. Am J Epidemiol 108:367-372
23. Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E 2007 Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol (Oxf) 66:626-631
24. Cox D 1972 Regression models and life tables with discussion. J R Stat Soc (B) 34:187-220
25. Woodward M 2005 Epidemiology: study design and data analysis. 2nd ed. Boca Raton, FL: Chapman, Hall/CRC
26. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R, Seppälä M 1996 Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98:2612-2615
27. Hong Y, Pedersen NL, Brismar K, Hall K, de Faire U 1996 Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 81:1791-1797
28. Swerdlow AJ, Higgins CD, Adlard P, Preece MA 2002 Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 360:273-277
29. Smith GD, Gunnell D, Holly J 2000 Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ 321:847-848
30. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
31. Harrela M, Koistinen R, Tuomilehto J, Nissinen A, Seppälä M2000 Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men. Ann Med 32:424-428
32. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E 2000 Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592-1600